Nomegestrol acetate-17b-estradiol for oral contraception

Patient Preference and Adherence

Volumn 7, Issue , 2013, Pages 607-619

  Burke, Anne ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Estradiol; Nomegestrol acetate; Oral contraception

Indexed keywords

ANTICONVULSIVE AGENT; CYTOCHROME P450; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL PLUS NOMEGESTROL ACETATE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FOLLITROPIN; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NOMEGESTROL ACETATE; PROGESTERONE; RIFAMPICIN;

ACNE; AGE; AMENORRHEA; BODY MASS; BONE DENSITY; CHOLESTEROL BLOOD LEVEL; CONDOM; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HEMATOLOGICAL PARAMETERS; HORMONE INHIBITION; HUMAN; HYDROCORTISONE BLOOD LEVEL; INCIDENCE; INSULIN BLOOD LEVEL; MAXIMUM PLASMA CONCENTRATION; MENSTRUAL IRREGULARITY; METABOLIC PARAMETERS; METRORRHAGIA; MULTIPLE CYCLE TREATMENT; OBESITY; ORAL CONTRACEPTION; OVULATION INHIBITION; PATIENT COMPLIANCE; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SIDE EFFECT; SPOTTING; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL BLOOD LEVEL; VENOUS THROMBOEMBOLISM; WEIGHT GAIN; WITHDRAWAL BLEEDING;

EID: 84879771011     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S39371     Document Type: Review

References (44)

1. United Nations Department of Economic and Social Affairs, Population Division. World contraceptive use 2011. Available from: http://www.un.org/esa/population/publications/contraceptive2011/wallchart_front.pdf. Accessed November 14, 2012.
2. Trussell J. Contraceptive failure in the United States. Contraception. 201;83:397-404.
3. Sitruk-Ware R, Nath A. Metabolic effects of contraceptive steroids. Rev Endocr Metab Disord. 2011;12:63-75.
4. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 beta-estradiol. Fertil Steril. 1993;60:616-619.
5. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890.
6. Raymond EG, Burke AE, Espey E. Combined hormonal contraceptives and venous thromboembolism: putting the risks into perspective. Obstet Gynecol. 2012;119:1039-1044.
7. Conard J, Basdevant A, Thomas JL, et al. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebocontrolled study with nomegestrol acetate and estradiol. Fertil Steril. 1995;64:957-962.
8. Coutinho EM, de Souza JC, Athayde C, et al. Multicenter clinical trial on the efficacy and acceptability of a single contraceptive implant of nomegestrol acetate, Uniplant. Contraception. 1996;53:121-125.
9. Ruan X, Seeger H, Mueck AO. The pharmacology of nomegestrol acetate. Maturitas. 2012;71:345-353.
10. Yang LP, Plosker GL. Nomegestrol acetate/estradiol: in oral contraception. Drugs. 2012;72:1917-1928.
11. Stanczyk FZ. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocr Metab Disord. 2002;3:211-224.
12. Djerassi C. Steroid oral contraceptives. Science. 1966;151: 1055-1061.
13. Jensen JT. Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest. Expert Opin Pharmacother. 2010;11:1147-1157.
14. Sandset PM, Høibraaten E, Eilertsen AL, Dahm A. Mechanisms of thrombosis related to hormone therapy. Thromb Res. 2009;123 Suppl 2: S70-S73.
15. Burkman R, Bell C, Serfaty D. The evolution of combined oral contraception: improving the risk to benefit ratio. Contraception. 2011;84:19-34.
16. Zeun S, Lu M, Uddin A, Zeiler B, Morrison D, Blode H. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care. 2009;14:221-232.
17. Endrikat J, Parke S, Trummer D, Schmidt W, Duijkers I, Klipping C. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception. 2008;78: 218-225.
18. Duijkers IJ, Klipping C, Grob P, Korver T. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol. Eur J Contracept Reprod Health Care. 2010;15:314-325.
19. Chretien FC, Dubois R. Effect of nomegestrol acetate on spinability, ferning and mesh dimension of midcycle cervical mucus. Contraception. 1991;43:55-65.
20. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2008;61:171-180.
21. Lello S. Nomegestrol acetate: pharmacology, safety profile and t{stroke}herapeutic efficacy. Drugs. 2010;70:541-559.
22. Gerrits MG, Schnabel PG, Post TM, Peeters PA. Pharmacokinetic profile of nomegestrol acetate and 17b-estradiol after multiple and single dosing in healthy women. Contraception. August 13, 2012. [Epub ahead of print.]
23. Chabbert-Buffet N, Chassard D, Ochsenbein E, Thomas JL, Christin-Maitre S. Inhibition of ovulation by NOMAC/E2, a novel monophasic oral contraceptive combining nomegestrol acetate and 17β-oestradiol: a double-blind, randomised, dose-finding pilot study. Eur J Contracept Reprod Health Care. 2011;16:76-84.
24. Gladwell M. John Rock's Error. The New Yorker, March 13, 2000. Available from: http://www.newyorker.com/archive/2000/03/13/2000_03_13_052_TNY_LIBRY_000020393. Accessed November 16, 2012.
25. Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ ethinyl estradiol 20 micro g (Loestrin 24 Fe). Contraception. 2007;75: 16-22.
26. Baerwald AR, Pierson RA. Ovarian follicular development during the use of oral contraception: a review. J Obstet Gynaecol Can. 2004;26: 19-24.
27. Christin-Maitre S, Serfaty D, Chabbert-Buffet N, Ochsenbein E, Chassard D, Thomas JL. Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17β-estradiol (NOMAC/E2): a double-blind, randomized study. Hum Reprod. 2011;26:1338-1347.
28. Westhoff C, Kaunitz AM, Korver T, et al. Eff icacy, safety, and t{stroke}olerability of a monophasic oral contraceptive containing nomegestrol acetate and 17β-estradiol: a randomized controlled trial. Obstet Gynecol. 2012;119:989-999.
29. Mansour D, Verhoeven C, Sommer W, et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care. 2011;16: 430-443.
30. World Health Organization. Medical Eligibility Criteria for Contraceptive Use, Fourth Edition, 2009. Available from: http://www.who.int/reproductivehealth/publications/family_planning/9789241563888/en. Accessed November 13, 2012.
31. Read CM. New regimens with combined oral contraceptive pills-moving away from traditional 21/7 cycles. Eur J Contracept Reprod Health Care. 2010;15 Suppl 2:S32-S41.
32. Basdevant A, Pelissier C, Conard J, Degrelle H, Guyene TT, Thomas JL. Effects of nomegestrol acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women. Contraception. 1991;44:599-605.
33. Ågren UM, Anttila M, Mäenpää-Liukko K, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorg-estrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur J Contracept Reprod Health Care. 2011;16: 444-457.
34. Ågren UM, Anttila M, Mäenpää-Liukko K, et al. Effects of a mono-phasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function. Eur J Contracept Reprod Health Care. 2011;16:458-467.
35. Sørdal T, Grob P, Verhoeven C. Effects on bone mineral density of a monophasic combined oral contraceptive containing nomegestrol acetate/17β-estradiol in comparison to levonorgestrel/ethinylestradiol. Acta Obstet Gynecol Scand. 2012;91:1279-1285.
36. Nguyên-Pascal ML, Thomas JL, Bergougnoux L, Garnero P, Drapier-Faure E, Delmas PD. Nomegestrol acetate may enhance the skeletal effects of estradiol on biochemical markers of bone turnover in meno-pausal women after a 12-week treatment period. Climacteric. 2005;8: 136-145.
37. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2012;7:CD004425.
38. Stanczyk FZ. All progestins are not created equal. Steroids. 2003;68: 879-890.
39. Sitruk-Ware R, Nath A. The use of newer progestins for contraception. Contraception. 2010;82:410-417.
40. Mueck AO, Sitruk-Ware R. Nomegestrol acetate, a novel progestogen for oral contraception. Steroids. 2011;76:531-539.
41. Gaussem P, Alhenc-Gelas M, Thomas JL, et al. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol,compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. Thromb Haemost. 2011;105:560-567.
42. Grimes DA, Schulz KF, Raymond EG. Surrogate end points in women's health research: science, protoscience, and pseudoscience. Fertil Steril. 2010;93:1731-1734.
43. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost. 2003;89:493-498.
44. Holt VL, Scholes D, Wicklund KG, Cushing-Haugen KL, Daling JR. Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol. 2005;105:46-52.